Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria

Ayyagari, Raj; Powell, Taylor; Staib, Lawrence H.; Chapiro, Julius; Perez-Lozada, Juan Carlos; Bhatia, Shivank; Chai, Toby C.; Schoenberger, Steven; Devito, Ralph

doi:10.1016/j.urology.2019.11.003

Cited by 17 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, similar results were found, with 80% of catheter-dependent becoming catheter-free 3 months after undergoing PAE [ 23 ]. Comparable results were found in another study showing 33 out of 38 (87%) of catheter-dependent patients capable of being catheter-free after 3 months [ 19 ].…”

Section: Indicationssupporting

confidence: 69%

See 1 more Smart Citation

Prostate Artery Embolization—Review of Indications, Patient Selection, Techniques and Results

Naidu

Narayanan

Saini

et al. 2021

JCM

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) due to benign prostatic hypertrophy (BPH) are a very common problem in men ranging from mild urinary symptoms to recurrent urinary tract infections or renal failure. Numerous treatment options are available ranging from conservative medical therapies to more invasive surgical options. Prostate artery embolization (PAE) has emerged as a novel treatment option for this common problem with clinical efficacy comparable to the current surgical gold standard, transurethral resection of the prostate (TURP). PAE offers fewer complications and side effects without a need for general anesthesia or hospitalization. This review discusses the indications for prostate artery embolization in addition to LUTS, patient evaluation in patients with LUTS, PAE technique and clinical results, with an emphasis on efficacy and safety.

show abstract

Section: Indicationssupporting

confidence: 69%

“…This demonstrated resolution of the hematuria in 85% of patients at 3 months and 80% at 12 months [ 18 ]. In a different study evaluating gross hematuria in BPH patients, 34 out of 37 (92%) patients were hematuria-free 483 ± 137 days after undergoing PAE [ 19 ].…”

Section: Indicationsmentioning

confidence: 99%

Prostate Artery Embolization—Review of Indications, Patient Selection, Techniques and Results

Naidu

Narayanan

Saini

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Last, adverse events during follow-up were reported according to the Society of Interventional Radiology (SIR) classification as minor (A and B) or major [ 20 , 21 ] and according to the Clavien–Dindo grading system as minor (I and II) or major (III, IV, V) [ 22 , 23 ].…”

Section: Methodsmentioning

confidence: 99%

Prostate Artery Embolization Using N-Butyl Cyanoacrylate Glue for Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Valid Alternative to Microparticles?

Loffroy¹,

Guillen²,

Salet

et al. 2021

JCM

View full text Add to dashboard Cite

Our goal was to evaluate the feasibility, safety, and short-term outcomes of prostate artery embolization (PAE) with N-butyl cyanoacrylate (NBCA) glue as the only embolic agent in patients with benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTSs). A two-center retrospective study of 50 patients (mean age, 67.6 ± 7.4 years; range, 54–85 years) treated with NBCA between 2017 and 2020 was conducted. PAE was performed using a mixture of Glubran 2 glue and Lipiodol in a 1:8 ratio, under local anesthesia, on an outpatient basis, after cone-beam computed tomography vascular mapping. Mean total injected NBCA/Lipiodol volume was 0.9 ± 0.3 mL, total injection time was 21.9 ± 7.8 s, and total radiation dose was 18,458 ± 16,397 mGy·cm. Statistically significant improvements over time occurred for the International Prostate Symptoms Score (9.9 ± 6.8 versus 20.5 ± 6.7, p = 0.0001), quality-of-life score (2.2 ± 1.5 versus 4.9 ± 1.0, p = 0.0001), prostate-specific antigen level (4.6 ± 3.0 versus 6.4 ± 3.7, p = 0.0001), and prostate volume (77.3 ± 30.5 versus 98.3 ± 40.2, p = 0.0001) at a median of 3 months versus baseline. Minor adverse events developed in 11/50 (22%) patients, but no major complications occurred. The International Index of Erectile Function did not change significantly. PAE with NBCA is feasible, safe, fast, and effective for patients with BPH-related LUTSs. Prospective comparative studies with longer follow-ups are warranted.

show abstract

“…Multiple studies have shown the safe, effective, and durable effect of PAE in patients with urinary retention [28][29][30][31][32][33]. In those studies, between 70 and 91% of patients with urinary retention were able to void spontaneously after PAE.…”

Section: Discussionmentioning

confidence: 99%

Prostatic Artery Embolization (PAE) Using Polyethylene Glycol Microspheres: Safety and Efficacy in 81 Patients

Insausti¹,

Galbete

Lucas‐Cava

et al. 2022

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of prostatic artery embolization (PAE) using polyethylene glycol microspheres (PEGM) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Materials and methods This multicentric prospective study enrolled 81 patients who underwent PAE with 400 ± 75 µm PEGM (HydroPearl®, Terumo, Japan). Results from baseline and 1-, 3-, 6-, and 12-month follow-ups were assessed for subjective outcomes including International Prostate Symptoms Score (IPSS), Quality of life (QoL), and International Index of Erectile Function, and objective outcomes such as peak urinary flow (Qmax) and post-void residual volume (PVR). The visual analogue scale, satisfaction questionnaire, prostatic volume, and prostatic specific antigen levels were also evaluated. Complications were documented using the modified Clavien–Dindo classification. Results Technical success was obtained in all patients. Clinical success was achieved in 78.5% of patients. Before PAE, 54.3% of patients had an indwelling catheter which was removed in 75% of them after procedure. A statistically significant decrease was observed in IPSS and QoL from baseline to 12 months (20.14 vs 5.89; 4.8 vs 0.63, P < .01), respectively. Objective outcomes also showed a statistically significant improvement in Qmax (+ 114.9%; P < .01), achieving a maximum urinary flow of 14.2 mL/sec, and PVR (decrease 58%; P < .05) at 12 months. Minor complications (Clavien–Dindo grades I–II) occurred in 13.6% of patients, without major complications observed. Conclusion PAE with PEGM is safe and effective treatment in patients with symptomatic BPH, with a significant improvement in both subjective and objective outcomes.

show abstract

Prostatic Artery Embolization in Nonindex Benign Prostatic Hyperplasia Patients: Single-center Outcomes for Urinary Retention and Gross Prostatic Hematuria

Cited by 17 publications

References 25 publications

Prostate Artery Embolization—Review of Indications, Patient Selection, Techniques and Results

Prostate Artery Embolization—Review of Indications, Patient Selection, Techniques and Results

Prostate Artery Embolization Using N-Butyl Cyanoacrylate Glue for Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Valid Alternative to Microparticles?

Prostatic Artery Embolization (PAE) Using Polyethylene Glycol Microspheres: Safety and Efficacy in 81 Patients

Contact Info

Product

Resources

About